ResApp Receives Notice of Acceptance for Core Patent...

ResApp Receives Notice of Acceptance for Core Patent in
Australia
Brisbane, Australia, 15 August 2018 -- ResApp Health Limited (ASX:RAP), a leading digital
health company developing smartphone applications for the diagnosis and management of
respiratory disease, is pleased to announce that IP Australia has issued a Notice of Acceptance
for its patent application 2013239327 titled “Method and Apparatus for Processing Patient
Sounds” covering the use of a cough sound based audio processing pipeline for diagnosing
respiratory disease. The patent protects a key component of ResAppDx, ResApp’s smartphone
application for diagnosing acute respiratory disease, and has an expiry date of 28 March 2033.
This patent is the second member of the patent family to be accepted, following the recently
received Notice of Allowance from the United States Patent and Trademark Office. Patent
applications covering similar subject matter are pending in Europe, Japan, China and South
Korea.
Tony Keating, CEO and Managing Director of ResApp, commented, “We are pleased to have now
secured a strong patent position in both Australia and the United States, two of our target
markets for commercialisation. With patents from this family also pending in other major target
markets, including Europe and China, we are creating a robust intellectual property position as
we move closer to regulatory approval and market entry.”
ResApp has also filed or has exclusive license to three other patent applications which are at
either provisional or Patent Cooperation Treaty (PCT) application stage.
About


GLTAH